Detailed examination of the non small cell lung cancer pipeline products, key players involved and enlists all their major and minor projects

The report provides comprehensive information on the therapeutics under development for Non-Small Cell Lung Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Key Players discussed in Non-Small Cell Lung Cancer - Pipeline Review, H1 2016 Report are -

3-V Biosciences, Inc.,4SC AG ,AbbVie Inc. ,Ability Pharmaceuticals, S.L.,ACEA Biosciences, Inc.,Acetylon Pharmaceuticals, Inc.,Adaptimmune Therapeutics Plc,Advanced Cancer Therapeutics,Advenchen Laboratories, LLC,Aeolus Pharmaceuticals, Inc.,Altimmune, Inc.

,Altor BioScience Corporation,Amgen Inc. ,Andarix Pharmaceuticals, Inc.,AndroScience Corporation,Apac Biotech Pvt Ltd,APO-T B.V.

,Aptose Biosciences Inc.,Argos Therapeutics, Inc.,Ariad Pharmaceuticals, Inc.,Arog Pharmaceuticals, Inc.,ArQule, Inc. ,Array BioPharma Inc.,Arrien Pharmaceuticals, LLC,Astellas Pharma Inc.,Asterias Biotherapeutics, Inc.,Astex Pharmaceuticals, Inc.,AstraZeneca Plc ,ATLAB Pharma SAS,Aurigene Discovery Technologies Limited,AVEO Pharmaceuticals, Inc.,Azaya Therapeutics, Inc.,Basilea Pharmaceutica AG,Batu Biologics, Inc.,Bavarian Nordic A/S,Bayer AG ,BeiGene, Ltd.

,Benitec Biopharma Limited,BerGenBio AS ,Beta Pharma, Inc. ,Betta Pharmaceuticals Co. Ltd.,BIND Therapeutics, Inc.,Bio-Path Holdings, Inc.,BIOCAD ,BioCancell Ltd ,BioLineRx, Ltd.

,Bionovis SA ,Blueprint Medicines Corporation,Boehringer Ingelheim GmbH,Boston Biomedical, Inc.,Bristol-Myers Squibb Company,Calithera Biosciences, Inc.,CanBas Co., Ltd. ,Cantargia AB ,Cantex Pharmaceuticals, Inc.,CASI Pharmaceuticals Inc.,Celgene Corporation,CellAct Pharma GmbH,Cellceutix Corporation,Celldex Therapeutics, Inc.,Cellectar Biosciences, Inc.,Cellectis S.A.

,Cellmid Limited ,Celltrion, Inc. ,Cellular Biomedicine Group, Inc.,Chipscreen Biosciences Ltd,Chugai Pharmaceutical Co., Ltd.,Cipla Ltd.

,Clonz Biotech Private Limited,Coherus BioSciences, Inc.,Corcept Therapeutics Incorporated,Cornerstone Pharmaceuticals, Inc.,Corvus Pharmaceuticals, Inc.,Critical Outcome Technologies Inc.,CTI BioPharma Corp.,CureVac GmbH ,CytRx Corporation,Daiichi Sankyo Company, Limited,DanDrit Biotech A/S,Debiopharm International SA,DEKK-TEC, Inc. ,DelMar Pharmaceuticals, Inc.,Denovo Biopharma, LLC,DiNonA Inc.

,Domainex Limited ,DormaTarg, Inc. ,Double Bond Pharmaceutical International AB,Dr.

Reddy's Laboratories Limited,Eagle Pharmaceuticals, Inc.,EirGenix Inc. ,Eisai Co., Ltd. ,Eleison Pharmaceuticals LLC,Eli Lilly and Company,Endocyte, Inc.

,EnGeneIC Ltd ,EntreChem, S.L. ,Enumeral Biomedical Holdings, Inc.,Eudendron S.r.l. ,Exelixis, Inc. ,F. Hoffmann-La Roche Ltd.,FibroStatin SL ,Five Prime Therapeutics, Inc.,Fujifilm Corporation,G&E Herbal Biotechnology Co., Ltd.,Ganymed Pharmaceuticals AG,Gene Techno Science Co., Ltd.,Genelux Corporation,Genentech, Inc.

,Genmab A/S ,Genor BioPharma Co., Ltd.,Genosco ,Genzyme Corporation,Gilead Sciences, Inc.,GlaxoSmithKline Plc,Globeimmune, Inc.,GlycaNova Norway AS,Glycotope GmbH ,Golden Biotechnology Corp.,Gradalis Inc. ,Halozyme Therapeutics, Inc.,Hanmi Pharmaceuticals, Co.

Ltd.,Hanmi Science Co., Ltd.,Heat Biologics, Inc.,HEC Pharm Co., Ltd.,Helix BioPharma Corp.,Heptares Therapeutics Limited,HitGen LTD ,Horizon Pharma Plc,Humanetics Corporation,Hutchison MediPharma Limited,iCeutica, Inc. ,Ideaya Biosciences, Inc.,Ignyta, Inc.

,Immune Design Corp.,Immune Pharmaceuticals Inc.,ImmunGene, Inc. ,ImmunoGen, Inc. ,Immunome Inc.

,Immunomedics, Inc.,Incuron, LLC ,Incyte Corporation,Infinity Pharmaceuticals, Inc.,Inflection Biosciences Limited,Inovio Pharmaceuticals, Inc.,Intas Pharmaceuticals Ltd.,Intezyne, Inc ,Inventiva ,IO Biotech ApS ,Io Therapeutics, Inc.,Jiangsu Hengrui Medicine Co., Ltd.,Jiangsu Kanion Pharmaceutical Co., Ltd.,Johnson & Johnson,Juno Therapeutics Inc.,Kadmon Corporation, LLC,Kolltan Pharmaceuticals, Inc.,Komipharm International Co., Ltd.,Kura Oncology, Inc.,Kyowa Hakko Kirin Co., Ltd.,Les Laboratoires Servier SAS,Loxo Oncology, Inc.,Mabion SA ,MacroGenics, Inc. ,Mallinckrodt Plc ,Mebiopharm Co., Ltd.,MedImmune, LLC ,Medinet Co., Ltd.

,Medisyn Technologies, Inc.,Medivation, Inc. ,Merck & Co., Inc. ,Merck KGaA ,Merrimack Pharmaceuticals, Inc.,Mersana Therapeutics, Inc.,Millennium Pharmaceuticals, Inc.,Mirati Therapeutics Inc.,Mirna Therapeutics, Inc.,Molecular Partners AG,MolMed S.p.A.

,Morphotek, Inc. ,Multimmune GmbH,Mycenax Biotech Inc.,NanoCarrier Co., Ltd.,Natco Pharma Limited,Nektar Therapeutics,Nemucore Medical Innovations, Inc.,NeoPharm Co., Ltd.,Netris Pharma S.A.S.,Neumedicines Inc.,NewLink Genetics Corporation,Nimbus Therapeutics, LLC,Northwest Biotherapeutics, Inc.,Novartis AG ,NuCana BioMed Limited,Omnitura Therapeutics Inc.,Oncobiologics, Inc.,Oncogenex Pharmaceuticals, Inc.,Oncolys BioPharma Inc.,Oncolytics Biotech Inc.,OncoMed Pharmaceuticals, Inc.,Ono Pharmaceutical Co., Ltd.,Onxeo SA ,Optimum Therapeutics, LLC,Oribase Pharma ,Oscotec Inc. ,OSE Immunotherapeutics,Oxford BioTherapeutics Ltd,Panacea Biotec Limited,Pfizer Inc.

,Pharma Mar, S.A. ,Pique Therapeutics,Plexxikon Inc. ,Polaris Pharmaceuticals, Inc.,Provectus Biopharmaceuticals, Inc.,PsiOxus Therapeutics Limited,Puma Biotechnology, Inc.,Purdue Pharma L.P.,Qu Biologics Inc.

,Reata Pharmaceuticals, Inc.,Recombio S.L ,Rexahn Pharmaceuticals, Inc.,Richter Gedeon Nyrt.,Samyang Holdings Corporation,Sanofi ,Sapvax ,Sareum Holdings Plc,Scinopharm Taiwan Limited,Shanghai Fosun Pharmaceutical (Group) Co., Ltd.,Shanghai Henlius Biotech Co., Ltd.,Shanghai Pharmaceutical Co., Ltd.,Shionogi & Co., Ltd.,SignPath Pharma Inc,Sihuan Pharmaceutical Holdings Group Ltd.,Sirnaomics, Inc. ,Sotio a.s. ,Spectrum Pharmaceuticals, Inc.,Sphaera Pharma Pvt.

Ltd.,STELIS Biopharma Pvt. Ltd.,Stemline Therapeutics, Inc.,Sumitomo Dainippon Pharma Co., Ltd.,Sun Pharma Advanced Research Company Ltd.,SuviCa Inc. ,Symic Biomedical, Inc.,Symphogen A/S ,Syndax Pharmaceuticals, Inc.

Additionally, the report provides an overview of key players involved in therapeutic development for Non-Small Cell Lung Cancer and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Access Complete report of 2025 pages @ www.rnrmarketresearch.com/contact…ame=647175

Scope

• The report provides a snapshot of the global therapeutic landscape of Non-Small Cell Lung Cancer
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved Non-Small Cell Lung Cancer therapeutics and enlists all their major and minor projects
• The report assesses Non-Small Cell Lung Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news related to pipeline therapeutics for Non-Small Cell Lung Cancer

Inquire more about this market research report @ www.rnrmarketresearch.com/contact…ame=647175

Reasons to access

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand important and diverse types of therapeutics under development for Non-Small Cell Lung Cancer
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Non-Small Cell Lung Cancer pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline